Scopus BioPharma is a clinical-stage biopharmaceutical company developing therapeutics targeting diseases. Co. has launched its Duet BioTherapeutics, Inc., which integrates the management and clinical development of immunotherapy (the Duet Platform). Co. has several licenses, a research agreement and a clinical research support agreement relating to the Duet Platform with City of Hope. The Duet Platform is comprised of complementary bifunctional oligonucleotides that each consist of a toll-like receptor 9 agonist linked with a signal transducer and activator of transcription 3 inhibitor: RNA silencing, CpG-STAT3siRNA; antisense, CpG-STAT3ASO; and DNA-binding inhibitor, CpG-STAT3decoy. The SCPS average annual return since 2020 is shown above.
The Average Annual Return on the SCPS average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SCPS average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SCPS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|